mirvetuximab
immunogen
[]
no phase iii in history has shown os in platinum resistant ovary. elahere comes to first line recurrence showing os benefit with 67% in hazard in preselected pop fra (&gt;75% +) #asco23 fra testing should precede alternatives like aurelia taxol/bev (pfs hr .48 but no os) 
Gynecologic Oncologist @Moffittnews. Targeted Therapy Explorer. Trained @MDAndersonnews #gyncsm. Views are mine alone.